Your session is about to expire
← Back to Search
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia
Phase 4
Waitlist Available
Led By Martin Taylor, DO, PHD
Research Sponsored by The Orthopedic Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial
Summary
This trial is testing Ingrezza, a medication that may help people with cervical dystonia, a condition causing involuntary neck movements. The study will last a few months and involve periodic check-ups. The medication works by balancing brain chemicals to improve muscle control.
Eligible Conditions
- Torticollis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 16 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in incidence of pain/spasm
Awards & Highlights
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
1Treatment groups
Experimental Treatment
Group I: IngrezzaExperimental Treatment1 Intervention
Participants will receive Ingrezza orally once daily for 12 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ingrezza Pill
2021
Completed Phase 4
~20
Find a Location
Who is running the clinical trial?
The Orthopedic FoundationLead Sponsor
Martin Taylor, DO, PHDPrincipal Investigatorprinciple investigator